Pfizer starts phase 1 study with Recifercept
2020-10-07Research
Phase 1 Study to Evaluate The Pharmacokinetics, Safety, And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept is now active.
Vosoritide phase 3 clinical trial data have been published
2020-09-30Research
Results from the phase 3 clinical trial for vosoritide, that involved children with achondroplasia with ages between 5 to 18 years have been published.
First orphan drug for achondroplasia is validated
2020-08-14Research
The European Medicines Agency (EMA) validated BioMarin's Marketing Authorization Application for Vosoritide to treat Children with Achondroplasia
RIBOMIC starts testing RBM-007 for achondroplasia
2020-07-22Research
RIBOMIC Announced dosing of the first person with RBM-007 in a Phase 1 Clinical Trial for Achondroplasia.
New drug application for achondroplasia by Ribomic
2020-04-23Research
RIBOMIC Announced submission of RBM-007 for Treatment of Achondroplasia
Positive feedback - EMA patient consultation on achondroplasia
2020-02-04Research
In December 2019, EMA prepared a public hearing to evaluate achondroplasia treatment plan. And more than 100 individuals participated.
